Heike Fuhrmann-Stroissnigg

TL;DR: The results demonstrate the feasibility of selectively ablating senescent cells and the efficacy of senolytics for alleviating symptoms of frailty and extending healthspan.

TL;DR: It is demonstrated that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered, and fibrotic lung disease is mediated, in part, by senescent cells.

TL;DR: The hypothesis‐driven, bioinformatics‐based approach used to discover that dasatinib (D) and quercetin (Q) are senolytic can be extended to increase the repertoire ofsenolytic drugs, including additional cell type‐specific senolytics agents.

TL;DR: Administration of fisetin to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology, and extended median and maximum lifespan, suggesting the feasibility to translation to human clinical studies.

TL;DR: Treatment of Ercc1−/∆ mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan, delayed the onset of several age-related symptoms and reduced p16INK4a expression, demonstrating the utility of a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells.